151 related articles for article (PubMed ID: 37816643)
1. Teaching NeuroImage: Severe Amyloid-Related Imaging Abnormalities After Anti-β-Amyloid Monoclonal Antibody Treatment.
Bonomi S; Samara A; Balestra N; Padalia A; Benzinger TL; Kang P
Neurology; 2023 Dec; 101(23):1079-1080. PubMed ID: 37816643
[No Abstract] [Full Text] [Related]
2. CMS coverage decision on anti-amyloid monoclonal antibodies for Alzheimer disease.
Knopman D; Sano M; Feldman HH
Nat Rev Neurol; 2022 Jul; 18(7):379-380. PubMed ID: 35596071
[No Abstract] [Full Text] [Related]
3. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
van Dyck CH
Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
Rabinovici GD; La Joie R
JAMA; 2023 Aug; 330(6):507-509. PubMed ID: 37459124
[No Abstract] [Full Text] [Related]
5. [Advances in anti-beta antibody treatment of Alzheimer's disease].
Zhang JH; Liang P
Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):633-5. PubMed ID: 18070457
[No Abstract] [Full Text] [Related]
6. Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta.
Wang J; Hara H; Makifuchi T; Tabira T
J Alzheimers Dis; 2008 Jun; 14(2):161-73. PubMed ID: 18560128
[TBL] [Abstract][Full Text] [Related]
7. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
Solomon B
Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.
Wang YJ
Nat Rev Neurol; 2014 Apr; 10(4):188-9. PubMed ID: 24638135
[No Abstract] [Full Text] [Related]
9. Identification of amyloid antibodies for Alzheimer disease - immunotherapy.
Huwait EA; Baghallab IM; Glabe CG; Abulnaja KO; Kumosani TA; Moselhy SS
Arch Physiol Biochem; 2022 Oct; 128(5):1275-1282. PubMed ID: 32449861
[TBL] [Abstract][Full Text] [Related]
10. Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology.
Solomon B; Frenkel D
J Neural Transm Suppl; 2002; (62):321-5. PubMed ID: 12456075
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo A; Lopera F
Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044
[TBL] [Abstract][Full Text] [Related]
12. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
[TBL] [Abstract][Full Text] [Related]
13. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
14. Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
Gandy S; Ehrlich ME
N Engl J Med; 2023 Jan; 388(1):80-81. PubMed ID: 36599066
[No Abstract] [Full Text] [Related]
15. Monoclonal antibody to the C-terminus of beta-amyloid.
Yang F; Mak K; Vinters HV; Frautschy SA; Cole GM
Neuroreport; 1994 Oct; 5(16):2117-20. PubMed ID: 7865758
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain.
Hatami A; Albay R; Monjazeb S; Milton S; Glabe C
J Biol Chem; 2014 Nov; 289(46):32131-32143. PubMed ID: 25281743
[TBL] [Abstract][Full Text] [Related]
17. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
18. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
19. Genentech's Alzheimer's antibody trial to study disease prevention.
Garber K
Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696
[No Abstract] [Full Text] [Related]
20. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
